MOXATAG

MOXATAG™ (amoxicillin extended-release) Tablets, 775 mg is a penicillin-class antibacterial indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes (S. pyogenes) in adults and pediatric patients 12 years and older.1 MOXATAG is the first and only amoxicillin formulation to be approved for once-daily use, providing convenience that may potentially lead to improved patient compliance.1-3 Once-daily dosing with MOXATAG advances traditional treatment with amoxicillin, a drug that has been trusted and relied upon for decades.1,4

The new, once-daily amoxicillin dosing of MOXATAG is made possible because of efficient drug delivery achieved through proprietary extended-release drug delivery technology.1 This innovative drug delivery technology allows for efficient treatment with antibiotics by providing efficacy at lower doses, as well as convenient once-daily dosing.4 Once-daily MOXATAG has been shown to demonstrate efficacy and safety comparable to penicillin VK QID in the treatment of streptococcal tonsillitis and/or pharyngitis in patients 12 years and older.1

Prescribing Information (PDF)

For more information including full prescribing information, visit www.moxatag.com.

1. MOXATAG Prescribing Information. MiddleBrook Pharmaceuticals, Inc. 2008.
2. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49(6):897-903.
3. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious disease. Infect Agents Dis. 1994;3(5):226-273.
4. Data on file, MiddleBrook Pharmaceuticals, Inc.